Improvement of Human Growth Hormone Immunoassay Using 125I.

Lambert, A. E.; Luyckx, A; Zahnd, G

doi:10.3181/00379727-126-32460

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…C-peptide levels were measured after the removal of proinsu-lin and alcoholic extraction [23]. Growth hormone concentration was determined by radioimmunoassay [24]. Pancreatic glucagon was measured with specific antiserum R4 which did not cross-react with porcine gut glucagon-like immunoreactivity in the physiological range [25].…”

Section: Methodsmentioning

confidence: 99%

Tolbutamide does not alter insulin requirement in Type 1 (insulin-dependent) diabetes

et al. 1984

View full text Add to dashboard Cite

We examined whether tolbutamide has any acute or short-term effects on insulin action in Type 1 (insulin-dependent) diabetes. A euglycaemic glucose clamp was performed in seven Type 1 diabetic patients without clinical insulin resistance by infusing glucose at a constant rate of 0.01 mmol X kg-1 X min-1 for 3h together with a simultaneous insulin infusion using an 'artificial pancreas'. The insulin infusion rate required to maintain blood glucose at 6.7 mmol/l at a set low glucose infusion rate provides an index of insulin action in vivo. The euglycaemic clamp was performed on 3 separate days in the same patient: (1) in the basal state; (2) during simultaneous intravenous tolbutamide infusion of 0.5 g/h, and (3) after treatment with 2.5 g tolbutamide/day for 6 days in addition to insulin. The insulin infusion rate needed to maintain the set blood glucose level did not differ significantly between the three experimental conditions (1.2 +/- 0.2 versus 1.3 +/- 0.3 versus 1.2 +/- 0.3 U/h). Plasma glucagon, growth hormone, non-esterified fatty acid and glycerol levels did not differ between control or sulphonylurea treatment studies. The results suggest that tolbutamide does not exert any acute or short-term effects on insulin action in vivo in Type 1 diabetes. Our results do not provide support for the idea that this agent is a clinically useful adjunct to insulin in such patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Tolbutamide does not alter insulin requirement in Type 1 (insulin-dependent) diabetes

et al. 1984

View full text Add to dashboard Cite

show abstract

“…Blood glucose was estimated by the AutoAnalyzer ferricyanide method (7). Plasma growth hormone and insulin concentrations were determined by double-antibody radioimmunoassays (24,30). Plasma immunoreactive glucagon was assayed (49) using an antipancreatic glucagon antiserum which purportedly measures true pancreatic glucagon (30-K antiserum, kindly provided by Dr. R. H. Unger, University of Texas South-Western Medical School, Dallas, Texas).…”

Section: Methodsmentioning

confidence: 99%

Plasma Growth Hormone, Insulin, and Glucagon Responses to Arginine Infusion in Children and Adolescents with Idiopathic Short Stature, Isolated Growth Hormone Deficiency, Panhypopituitarism, and Anorexia Nervosa

et al. 1975

View full text Add to dashboard Cite

ExtractThe effects of intravenous infusion of arginine (20 g/m2) after an overnight fast on plasma immunoreactive growth hormone (GH), insulin (IRI), and glucagon (IRG), and blood glucose were examined in five groups of children and adolescents: 10 normal individuals, 18 with idiopathic short stature, 6 with isolated growth hormone deficiency, 8 with panhypopituitarism, and 6 with anorexia nervosa.The mean fasting plasma GH concentration was significantly elevated in the group with anorexia nervosa (P < 0.05), and similar to the value for the normal group in all other groups. After arginine infusion, four-to sixfold increases of plasma G H were observed in the normal children, and similar increases were seen in those with idiopathic short stature as well as in those with anorexia nervosa; whereas, in the children with isolated growth hormone deficiency or panhypopituitarism, there was no significant increase in plasma GH. Fasting blood glucose concentrations were significantly lower than normal in subjects with isolated growth hormone deficiency ( P < 0.05), panhypopituitarism ( P < 0.001), and anorexia nervosa (P < 0.001), whereas fasting plasma IRI and IRG concentrations were similar to the values in the normal group. Plasma IRI increased eightfold at the end of the 30-min arginine infusion in the normal subjects; the increase was slightly but not significantly less in those with idiopathic short stature, and significantly less in those with isolated growth hormone deficiency ( P < 0.05), panhypopituitarism ( P < 0.001), and anorexia nervosa ( P < 0.05). Arginine infusion resulted in two-to threefold increases of plasma IRG in the normal group, and similar increases were observed in all of the other groups tested. These results suggest that whereas pancreatic P cell responsiveness may be deficient in children and adolescents with isolated growth hormone deficiency, panhypopituitarism, or anorexia nervosa, pancreatic a cell responsiveness, to arginine a t least, appears to be intact under these conditions. SpeculationAlthough plasma glucagon responses to arginine infusion were not less in subjects with hypopituitarism or anorexia nervosa than in normal subjects, relative hypoglucagonemia may have existed, since both basal and postarginine infusion plasma glucagon levels were not higher than normal in the presence of significantly lower blood glucose values. Thus, the present study does not exclude a deficient pancreatic a cell response to hypoglycemia. Alternatively, nonavailability of substrates for gluconeogenesis may have a more important influence than hormonal factors in the genesis of the hypoglycenia observed in these states.73

show abstract

“…Plasma glucose concentration was estimated by Beckman-Analyzer, NEFA according to Duncombe (1964) and glycerol concentration according to Eggstein and Kreutz (1966). Plasma insulin (IRI) and growth hormone (HGH) concentrations were measured by radioimmunoassay (Lambert et al, 1967;Gottschling et al, 1974). Pancreatic glucagon (IRG) concentration was estimated by using a specific antiserum R 4 which did not crossreact with procine gut-GLI in the physiological range (Schulz et al, 1978).…”

Section: Methodsmentioning

confidence: 99%

Metabolic and Hormonal Responses during a Glucose Contrlled Insulin Infusion (Biostator^®) in Subjects with Imparied Glucose Tolerance¹)

Kp¹,

Schneider²,

Peters³

et al. 2009

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Improvement of Human Growth Hormone Immunoassay Using 125I.

Cited by 6 publications

References 0 publications

Tolbutamide does not alter insulin requirement in Type 1 (insulin-dependent) diabetes

Tolbutamide does not alter insulin requirement in Type 1 (insulin-dependent) diabetes

Plasma Growth Hormone, Insulin, and Glucagon Responses to Arginine Infusion in Children and Adolescents with Idiopathic Short Stature, Isolated Growth Hormone Deficiency, Panhypopituitarism, and Anorexia Nervosa

Metabolic and Hormonal Responses during a Glucose Contrlled Insulin Infusion (Biostator^®) in Subjects with Imparied Glucose Tolerance¹)

Contact Info

Product

Resources

About

Improvement of Human Growth Hormone Immunoassay Using 125I.

Cited by 6 publications

References 0 publications

Tolbutamide does not alter insulin requirement in Type 1 (insulin-dependent) diabetes

Tolbutamide does not alter insulin requirement in Type 1 (insulin-dependent) diabetes

Plasma Growth Hormone, Insulin, and Glucagon Responses to Arginine Infusion in Children and Adolescents with Idiopathic Short Stature, Isolated Growth Hormone Deficiency, Panhypopituitarism, and Anorexia Nervosa

Metabolic and Hormonal Responses during a Glucose Contrlled Insulin Infusion (Biostator®) in Subjects with Imparied Glucose Tolerance1)

Contact Info

Product

Resources

About

Metabolic and Hormonal Responses during a Glucose Contrlled Insulin Infusion (Biostator^®) in Subjects with Imparied Glucose Tolerance¹)